Codexis announced today that Peter Ketelaar has joined the company as Director of Business Development, Europe.

In response to increasing global demand for Codexis’ products and technologies, Peter will be responsible for leading new business development activities in Europe, focusing on industry leaders in the pharmaceutical and life sciences sectors.

Mr. Ketelaar joins Codexis from DSM Biologics, where he most recently held the position of Director, New Business Development for Europe and Asia. During his 19-year tenure at DSM, Mr. Ketelaar conducted a variety of commercial activities, including worldwide marketing and sales, strategic business planning and market analysis, as well as new business development. Mr. Ketelaar’s business development efforts achieved significant growth in several major new markets for DSM, including the United Kingdom, Scandinavia, Israel and Japan. In parallel to these business development activities, Mr. Ketelaar also served as Chairman of the Business Ethics Committee of Corporate DSM. The Committee defined Guidelines for Ethical Behaviour for the whole Marketing, Sales & Purchase force of DSM. Prior to his commercial experience, Mr. Ketelaar had a leading role at DSM Research, focusing on optimization of enzyme utilization in DSM’s amino acid manufacturing process.

“We are delighted to welcome Peter to the Codexis’ expanding global Business Development team,” said Kevin Taylor, Vice President of Business Development at Codexis. “He brings extensive business development experience, particularly in growing new markets in Europe. We are confident Peter’s appointment will help us achieve our goal of expanding our relationships with key European pharmaceutical companies.”

Mr. Ketelaar received his BSc degree in Chemical Technology from HTS Leeuwarden, and his MSc degree in Chemistry from State University of Groningen.

About Codexis, Inc

Codexis, Inc., a majority owned subsidiary of Maxygen, Inc. (Nasdaq: MAXY), began operations as an independent company in 2002. Codexis provides biocatalysis and fermentation processes and products to the life sciences, chemical and allied industries. Codexis’ proprietary DNAShuffling™ and MolecularBreeding™ directed molecular evolution technology uses biocatalysis and fermentation to enable discovery and development of improved or novel processes for cost-effective synthesis of valuable pharmaceuticals and chemical compounds. Codexis has ten strategic alliances with world leaders in human therapeutics and chemical production, 15 potential products and processes in development internally or with partners, and five processes now operating at commercial scale.

MolecularBreeding is a trademark of Maxygen, Inc. Codexis is a trademark of Codexis, Inc.

Contact:
Codexis, Inc.
Tassos Gianakakos
Sr. Vice President, Business Development
T. +1-650-298-5423
F. +1-650-298-5449
tassos.gianakakos@codexis.com